What is GHK-Cu?

A copper-binding tripeptide your body already makes

GHK-Cu is short for glycyl-L-histidyl-L-lysine copper complex: three amino acids, glycine, histidine, and lysine, bound to a copper ion. It is not a lab invention. Researcher Loren Pickart identified it in human plasma in 1973 while studying why older liver tissue transplanted into a culture with young blood plasma started behaving more like young tissue. GHK-Cu turned out to be a major part of the answer.

Like a lot of the biology this site covers, the compound follows an age curve. Blood plasma levels run around 200 ng/mL in your 20s and fall to roughly 80 ng/mL by age 60, tracking the same decline seen in the body's wound-healing and tissue-repair capacity as it ages. That correlation is the entire premise behind supplementing it, whether topically or by injection.

How GHK-Cu is thought to work

The copper ion does real chemical work. It activates lysyl oxidase, the enzyme that cross-links collagen fibers into strong tissue, and superoxide dismutase, an antioxidant enzyme that neutralizes reactive oxygen species. Both are central to how skin and other tissue repair themselves.

The broader effect is at the gene level. A widely cited analysis by Pickart and colleagues, using the Broad Institute's Connectivity Map to screen GHK-Cu's effect on cultured human fibroblasts, found it modulates roughly 4,000 human genes, a large fraction of the genome segments tested. The pattern skews toward turning down genes tied to inflammation and tissue breakdown while turning up genes tied to repair and antioxidant defense. That is a strong, mechanistically coherent signal. It is also a cell-culture and computational finding, not a clinical outcome, and the gap between the two is exactly where this peptide's evidence record splits in two.

The topical evidence: what the skin trials actually found

This is the half of the GHK-Cu story with real human data behind it. The trial most dermatology reviews still cite is a 12-week study presented at the American Academy of Dermatology's 60th annual meeting in 2002, testing a GHK-Cu facial cream on 71 women with mild to advanced photoaging. Compared with a vehicle control, the GHK-Cu group showed measurable improvements in skin density, thickness, laxity, and fine lines, tracked by ultrasound and standard dermatology imaging.

That result has held up reasonably well since. Follow-up work from Pickart's own lab on the same fibroblast and collagen mechanisms describes topical GHK-Cu as consistently better tolerated than retinoids, with real, if modest, effects on collagen density and photoaging measures over 8 to 12 weeks of daily use. Nobody is claiming topical GHK-Cu rivals a prescription retinoid or an in-office procedure. The evidence supports a real, specific, small effect, which is more than most skincare ingredients marketed this heavily can say.

The injectable gap: where the evidence stops

Injectable GHK-Cu is a different product wearing the same name. No published randomized trial has tested it in humans for skin, hair, wound healing, or any systemic use, and no long-term human safety study exists for it at any dose. The 1 to 2 mg protocols showing up in peptide-clinic marketing are extrapolated from the topical trials and from animal dosing studies, not derived from a completed injectable human trial.

That is a meaningfully different evidence posture than saying a compound is unsafe. It means nobody has done the study, which is a distinct and more honest thing to tell a reader than either reassurance or alarm. It is the same gap this site has flagged for KPV and other peptides moving through the FDA's current compounding review: real preclinical or topical signal, and essentially nothing on the injectable human side.

The April 2026 FDA reclassification, and what it didn't do

On April 15, 2026, the FDA removed 12 peptides from Category 2 of the 503A bulk substances list, the bucket for compounds flagged with unresolved safety or efficacy concerns. Injectable GHK-Cu was one of them, alongside BPC-157 and TB-500. Removal from Category 2 lowers a regulatory barrier for licensed 503A compounding pharmacies. It does not mean the FDA reviewed and approved the compound, and it does not by itself authorize compounders to use it. That authorization requires a separate step: formal addition to the 503A list, which only happens after review by the FDA's Pharmacy Compounding Advisory Committee.

Here is where GHK-Cu's path diverges from the peptide getting most of the attention this year. BPC-157, TB-500, KPV, and four other substances went in front of that committee on July 23-24, 2026, and came away with a mix of votes for and against 503A inclusion. GHK-Cu was not on that agenda. It sits in a second group, alongside Melanotan II, DiHexa, PEG-MGF, and cathelicidin (LL-37), that the FDA has scheduled for its own advisory committee review before the end of February 2027. Until that meeting happens and the FDA issues a determination, GHK-Cu's regulatory status is exactly where it was the day after the April reclassification: one restriction lighter, with no affirmative green light.

Why GHK-Cu is on a slower clock than BPC-157

The FDA didn't explain publicly why it split the 12 reclassified peptides into two review groups on two different timelines, but the practical effect matters for anyone following the story. It means the injectable-GHK-Cu compounding market operates for at least another six-plus months under the same ambiguous footing it has now, not the clearer up-or-down answer BPC-157 and TB-500 got in July. Anyone tracking the broader peptide compounding landscape should treat GHK-Cu as a slower-moving, separate case, not a settled outcome of the July hearing.

What this means if you are considering GHK-Cu today

The two forms of this peptide deserve two different answers. Topical GHK-Cu is a legal, widely available, reasonably well-evidenced skincare ingredient. If the goal is skin density and collagen support, the trial record backs it up better than most ingredients sold alongside it.

Injectable GHK-Cu is a different decision entirely: an unproven product in humans, sold on the strength of a real mechanism and animal data rather than a completed safety trial, in a regulatory gray zone that will not clarify before 2027 at the earliest. If you go that route anyway, a licensed prescriber and a compounding pharmacy that provides a Certificate of Analysis is a materially safer path than an unregulated research-chemical vendor, the same rule that applies across every peptide in this category. It still does not substitute for the human trial that has not been run.